Award details

Commercialisation of anticancer agents capable of selectively targeting tumour vasculature.

Reference	BB/C524389/1
Principal Investigator / Supervisor	Professor Sylvie Ducki
Co-Investigators / Co-Supervisors	Dr Darren Brooks, Professor Alan McGown
Institution	University of Salford
Department	Biomedical Sciences Research Institute
Funding type	Research
Value (£)	50,812
Status	Completed
Type	Research Grant
Start date	01/08/2005
End date	31/07/2006
Duration	12 months

Abstract

unavailable

Summary

Tubulin (TUB) is an important target for cancer chemotherapy as it provides the scaffolding within cells maintaining their shape. By disrupting TUB, a cell's shape may be altered. When cells in the vasculature supplying tumours are targeted, blood flow is blocked starving the tumour to death. Previous BBSRC funding led to a QSAR model describing interactions between TUB and ligands populating its colchicine-binding site. Consequently we designed a series of chalcones able to selectively bind to this site inhibiting the assembly of TUB. These chalcones were also shown to possess selective tumour antivascular activity in vitro. We now wish to investigate the ADMET properties of the chalcones and improve their pharmacokinetic profile. The results would allow selecting the best candidate drugs for clinical development. This will significantly add to their commercial value and aid in attracting potential licensors to them, securing further development and clinical trials opportunities.

Committee	Closed Committee - Engineering & Biological Systems (EBS)
Research Topics	X – not assigned to a current Research Topic
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund (FOF) [2004-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search